Sam Brusco, Associate Editor07.18.23
ReddyPort has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ReddyPort elbow device used for non-invasive ventilation (NIV).
"ReddyPort's patented elbow is central to the ecosystem we are building to help mitigate clinical obstacles tied to NIV therapy from dry-mouth, oral biofilm accumulation to speech recognition," Tony Lair, ReddyPort CEO told the press.
The elbow has a self-sealing valve that offers seamless oral access to the mouth without needing mask removal to mitigate the risk of therapeutic pressure loss and maintain lung compliance. Clinicians can use ReddyPort’s oral care appliances (toothbrush, Yankauer, suction swab and applicator swabs) for routine Q2/Q4 oral care and dry mouth relief while reducing unplanned mask removal, which can lead to improperly fitted masks, pressure injuries, and refitting processes.
The elbow also lets clinicians and patients use the ReddyPort microphone, which amplifies audible speech noise while minimizing background noise.
NIV is the first line of therapy for respiratory insufficiency or failure, commonly seen with COPD, CHF, asthma, pneumonia, or ARDS. NIV is also used to wean patients off mechanical ventilation.
The ReddyPort elbow, according to the company, has safely delivered 45,000 compliant oral care sessions to patients under FDA emergency use authorization (EUA).
"ReddyPort's patented elbow is central to the ecosystem we are building to help mitigate clinical obstacles tied to NIV therapy from dry-mouth, oral biofilm accumulation to speech recognition," Tony Lair, ReddyPort CEO told the press.
The elbow has a self-sealing valve that offers seamless oral access to the mouth without needing mask removal to mitigate the risk of therapeutic pressure loss and maintain lung compliance. Clinicians can use ReddyPort’s oral care appliances (toothbrush, Yankauer, suction swab and applicator swabs) for routine Q2/Q4 oral care and dry mouth relief while reducing unplanned mask removal, which can lead to improperly fitted masks, pressure injuries, and refitting processes.
The elbow also lets clinicians and patients use the ReddyPort microphone, which amplifies audible speech noise while minimizing background noise.
NIV is the first line of therapy for respiratory insufficiency or failure, commonly seen with COPD, CHF, asthma, pneumonia, or ARDS. NIV is also used to wean patients off mechanical ventilation.
The ReddyPort elbow, according to the company, has safely delivered 45,000 compliant oral care sessions to patients under FDA emergency use authorization (EUA).